HomeCompareGNFT vs ADC

GNFT vs ADC: Dividend Comparison 2026

GNFT yields 22.35% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $94.7K in total portfolio value· pulled ahead in Year 9
10 years
GNFT
GNFT
● Live price
22.35%
Share price
$8.95
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$84.2K
Annual income
$8,592.87
Full GNFT calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — GNFT vs ADC

📍 ADC pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNFTADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNFT + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNFT pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNFT
Annual income on $10K today (after 15% tax)
$1,899.44/yr
After 10yr DRIP, annual income (after tax)
$7,303.94/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $61,373.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNFT + ADC for your $10,000?

GNFT: 50%ADC: 50%
100% ADC50/50100% GNFT
Portfolio after 10yr
$131.6K
Annual income
$44,695.08/yr
Blended yield
33.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

GNFT
Analyst Ratings
6
Buy
1
Sell
Consensus: Buy
Price Target
$13.00
+45.3% upside vs current
Range: $13.00 — $13.00
Altman Z
-0.1
Piotroski
2/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNFT buys
0
ADC buys
0
No recent congressional trades found for GNFT or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNFTADC
Forward yield22.35%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$84.2K$178.9K
Annual income after 10y$8,592.87$80,797.29
Total dividends collected$50.6K$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$13.00$81.06

Year-by-year: GNFT vs ADC ($10,000, DRIP)

YearGNFT PortfolioGNFT Income/yrADC PortfolioADC Income/yrGap
1$12,935$2,234.64$10,990$580.36+$1.9KGNFT
2$16,541$2,701.33$12,301$860.26+$4.2KGNFT
3$20,928$3,228.58$14,104$1,298.62+$6.8KGNFT
4$26,210$3,817.51$16,691$2,008.16+$9.5KGNFT
5$32,513$4,468.32$20,580$3,205.09+$11.9KGNFT
6$39,970$5,180.24$26,754$5,330.02+$13.2KGNFT
7$48,719$5,951.60$37,196$9,345.14+$11.5KGNFT
8$58,909$6,779.83$56,244$17,523.09+$2.7KGNFT
9← crossover$70,694$7,661.60$94,286$35,736.21$23.6KADC
10$84,236$8,592.87$178,949$80,797.29$94.7KADC

GNFT vs ADC: Complete Analysis 2026

GNFTStock

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Full GNFT Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this GNFT vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNFT vs SCHDGNFT vs JEPIGNFT vs OGNFT vs KOGNFT vs MAINGNFT vs NNNGNFT vs EPRTGNFT vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.